Keywords: Vernalis, Tris, Rx cough/cold product development, USA market

US Rx cough/cold deal boosts Vernalis

Article | 14 February 2012

Print This

UK biotech firm Vernalis (LSE: VER) saw its share price rocket 28% to 25.2 pence last Friday, when the company announced a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in